Immune checkpoint blocking therapy promotes a long-lasting anti-cancer response by releasing a block in the immune system including include anti-PD-1, anti-PD-L1, and anti-CTLA4 therapy (38–40). This evidence concerns the gene PDCD1 and cancer.